Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer

NCT07367581 | Recruiting

• 1 other identifier: AP2512-501-141-205
• Study Type: interventional
• Target: 70
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to compare the costotransverse foramen block (CTFB) with thoracic paravertebral block (TPVB) in patients undergoing thoracotomy for lung cancer.

Conditions

Costotransverse Foramen Block; Thoracic Paravertebral Block; Thoracotomy; Lung Cancer

Outcome Measures

Primary Outcomes (1)

• Total morphine consumption

  If the visual analog scale (VAS) is ≥ 4, rescue analgesics will be administered in the form of a 4 mg bolus of morphine.

  24 hours postoperatively

Secondary Outcomes (7)

• Duration of analgesia

  24 hours postoperatively

• Degree of pain

  48 hours postoperatively

• Intraoperative fentanyl consumption

  Intraoperatively

• Mean arterial blood pressure

  4 hours postoperatively

• Heart rate

  4 hours postoperatively

Study Arms (2)

CTFB Group

EXPERIMENTAL

Patients will receive an ipsilateral ultrasound-guided costotransverse foramen block with injection of 20 ml bupivacaine 0.25%.

Other: Costotransverse foramen block

TPVB Group

EXPERIMENTAL

Patients will receive an ipsilateral ultrasound-guided thoracic paravertebral plane block with injection of 20 ml bupivacaine 0.25%.

Other: Thoracic paravertebral plane block

Interventions

Costotransverse foramen block OTHER

Patients will receive an ipsilateral ultrasound-guided costotransverse foramen block with injection of 20 ml bupivacaine 0.25%.

CTFB Group

Thoracic paravertebral plane block OTHER

Patients will receive an ipsilateral ultrasound-guided thoracic paravertebral plane block with injection of 20 ml bupivacaine 0.25%.

TPVB Group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \> 18 years and ≤ 65 years old.
• American Society of Anesthesiologists (ASA) physical status II-III.
• Body mass index 18-35 kg/m2.
• Patients scheduled for thoracotomies for lung cancer.

You may not qualify if:

• Patient refusal.
• History of sensitivity to local anesthetics.
• History of psychological disorders.
• Contraindication to regional anesthesia, e.g., local sepsis, pre-existing peripheral neuropathies, and coagulopathy.
• Severe respiratory, cardiac, hepatic, or renal disease.
• Morbid obesity.
• Uncooperative patients.
• Patients on chronic pain therapy.

Sponsors & Collaborators

• National Cancer Institute, Egypt: lead

Study Sites (1)

Cairo University

Cairo, 12613, Egypt

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Mai M Elrawas, MD

CONTACT

00201222177242; mai.elrawas@nci.cu.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant professor of Anaesthesia, Intensive Care and Pain Management, National Cancer Institute, Cairo University Cairo University, Cairo, Egypt.

Study Record Dates

• First Submitted: January 17, 2026
• First Posted: January 26, 2026
• Study Start: January 24, 2026
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: January 27, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)